search
Back to results

Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion

Primary Purpose

Branch Retinal Vein Occlusion

Status
Completed
Phase
Phase 2
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Triamcinolone
Sponsored by
Shahid Beheshti University of Medical Sciences
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Branch Retinal Vein Occlusion focused on measuring Macular edema, Branch retinal vein occlusion, Intravitreal triamcinolone, Macular thickness, Retinal neovascularization

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Eyes suffering from branch retinal vein occlusion with less than 2 months duration. Exclusion Criteria: Monocularity, Previous intraocular surgery or laser therapy Glaucoma or ocular hypertension Significant media opacity Existence of traction on the macula Visual acuity ≥20/40 Signs of chronicity (such as cilioretinal and/or retinal shunt vessels)

Sites / Locations

  • Alireza Ramezani, MD

Outcomes

Primary Outcome Measures

Central macular thickness

Secondary Outcome Measures

Visual acuity
Retinal neovascularization
Intraocular pressure
Cataract progression

Full Information

First Posted
August 30, 2006
Last Updated
June 16, 2008
Sponsor
Shahid Beheshti University of Medical Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT00370266
Brief Title
Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion
Study Type
Interventional

2. Study Status

Record Verification Date
June 2008
Overall Recruitment Status
Completed
Study Start Date
February 2003 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
December 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Shahid Beheshti University of Medical Sciences

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine whether intraocular injection of triamcinolone is effective in the treatment of macular edema in acute branch retinal vein occlusion.
Detailed Description
Intravitreal triamcinolone has recently been shown to have beneficial effect on chronic macular edema due to vein occlusion and preventive effect on neovascularization. Hypothetically, prevention of macular derangement by reducing the amount of edema from early phase after occlusion until restoration of collaterals seems to be helpful in these eyes. To our knowledge, no prospective randomized clinical trial, considering both macular changes and preventive effect on neovascularization has been published for intravitreal triamcinolone in acute branch retinal vein occlusion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Branch Retinal Vein Occlusion
Keywords
Macular edema, Branch retinal vein occlusion, Intravitreal triamcinolone, Macular thickness, Retinal neovascularization

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Single
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Triamcinolone
Primary Outcome Measure Information:
Title
Central macular thickness
Secondary Outcome Measure Information:
Title
Visual acuity
Title
Retinal neovascularization
Title
Intraocular pressure
Title
Cataract progression

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Eyes suffering from branch retinal vein occlusion with less than 2 months duration. Exclusion Criteria: Monocularity, Previous intraocular surgery or laser therapy Glaucoma or ocular hypertension Significant media opacity Existence of traction on the macula Visual acuity ≥20/40 Signs of chronicity (such as cilioretinal and/or retinal shunt vessels)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alireza Ramezani, MD
Organizational Affiliation
Ophthalmic Research Center of Shaheed Beheshti Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alireza Ramezani, MD
City
Tehran
ZIP/Postal Code
16666
Country
Iran, Islamic Republic of

12. IPD Sharing Statement

Learn more about this trial

Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion

We'll reach out to this number within 24 hrs